After starting patients on bisphosphonates for osteoporosis, wait at least 3 years before ordering a repeat dual-energy x-ray absorptiometry (DXA) scan. Stength of recommendation: C: Based on a secondary analysis of a large randomized controlled trial

Hickner, John

Sharma, Umang

Stevermer, James J.

University of Missouri: MOspace

594 THE JOURNAL OF FAMILY PRACTICE  |   NOVEMBER 2009  |   VOL 58, NO 11Priority Updates from the Research Literature from the Family Physicians Inquiries NetworkMonitoring treatment: How often?Although recommendations for how often to monitor bone mineral density (BMD) after initiating treatment vary, the consensus has been that periodic monitoring is useful. But there have been no randomized trials evalu-ating BMD testing in patients taking bisphos-phonates. Th e use of DXA scans to identify osteo-porosis has been shown to be a cost-eff ective strategy in women older than 65 years,5  but there has not been a cost/benefi t analysis of follow-up DXA scanning after initiating treat-ment. Th e cost of a scan ranges from about $150 to $300, and it is not known how many patients undergo repeat DXA scanning after starting treatment. STUDY SUMMARYYearly scans are not helpfulTh e study we report on here is a secondary analysis of data from the Fracture Interven-tion Trial (FIT).6  In 1993, FIT randomized 6457 US women ages 55 to 80 years with low hip bone density to either alendronate or placebo.  Th e initial dose of alendronate was 5 mg/d, but was later increased to 10 mg/d when other studies found that the higher dose was more eff ective. FIT showed that alendronate increased BMD and decreased the risk of vertebral fracture.7  Bell et al1 used a mixed-model statistical analysis to compare “within-person varia-Bisphosphonate therapy: When not to monitor BMDMonitoring bone density within the fi rst 3 years of therapy does not provide useful information—and it is costly besides. PRACTICE CHANGERAfter starting patients on bisphosphonates for osteoporosis, wait at least 3 years before ordering a repeat dual-energy x-ray absorpti-ometry (DXA) scan.1 STRENGTH OF RECOMMENDATIONC: Based on a secondary analysis of a large randomized controlled trial. Bell KL, Hayen A, Macaskill P, et al. Value of routine monitoring of bone mineral density after starting bisphosphonate treatment: secondary analysis of treatment data. BMJ. 2009;338:b2266. ILLUSTRATIVE CASECASE  } Ms. K, a 68-year-old woman diag-nosed with osteoporosis on a screening DXA scan a year ago, has been taking a bisphos-phonate ever since. She’s anxious to know whether the medication is working and asks if it’s time for a repeat DXA scan. What should you tell her? Fragility fractures from osteoporosis are common in postmenopausal women. In the year 2000 alone, an estimated 9 million such fractures occurred worldwide.2 Treatment with bisphosphonates has been found to reduce the risk of fragility fractures,3 and the United States Preventive Services Task Force (USPSTF) recommends a DXA scan to screen for osteoporosis in women older than 65 years and some younger women at in-creased risk.4 Umang Sharma, MD Department of Family Medicine, TheUniversity of ChicagoJames J. Stevermer, MD, MSPHDepartment of Family and Community Medicine,University of Missouri-Columbia, FultonP U R L S  E D I T O RJohn Hickner, MD, MScDepartment of Family Medicine,Cleveland Clinic594_JFP1109   594 10/20/09   11:41:09 AM595JFPONLINE.COM VOL 58, NO 11  |  NOVEMBER 2009  |  THE JOURNAL OF FAMILY PRACTICEnate. Th is study advises us that it is not necessary to recheck BMD for at least 3 years after starting treatment. Elimination of early repeat DXA testing could result in signifi cant cost savings.CAVEATSFindings contradict usual recommendationsPhysicians should be aware that the conclu-sion of this study is not in line with recom-mendations from a number of prominent organizations. Th e American Association of Clinical Endocrinology,9 the National Osteo-porosis Foundation,10 and the North American Menopause Society11 all recommend follow-up DXA testing in 1 or 2 years. ❚ High-risk patient exception. Th e delay in repeat DXA testing may not be appropriate for patients at higher risk of bone density loss. However, a separate analysis of higher-risk groups was not done.  Finally, while the fi ndings of Bell et al suggest that we should wait at least 3 years before retesting, it is still not clear whether there is any benefi t to repeat DXA testing at any interval, given the nearly universal re-sponse rate. It is also possible that advances in DXA technology will reduce some of the variation in BMD results. CHALLENGES TO IMPLEMENTATIONAnxious patientsPatients like Ms. K may ask their physicians to retest well before 3 years. Yet those who undergo scanning after a shorter interval may be discouraged by early results. Advis-ing patients that the treatment is almost uni-formly eff ective in increasing BMD should reassure them that sticking with treatment is worthwhile.                   ACKNOWLEDGEMENTThe PURLs Surveillance System is supported in part by Grant Number UL1RR024999 from the National Center for Research Resources, a Clinical Translational Science Award to the University of Chicago. The content is solely the responsibility of the authors and does not necessarily represent the ofﬁ cial views of the National Center for Research Resources or the National Institutes of Health.tion” in BMD (variation in DXA results over time in individuals) and “between-person variation” in BMD (variation in DXA results over time in the population of patients). Th e BMD of all FIT par-ticipants in both the control and treatment groups was measured at baseline and at the 1-, 2-, and 3-year marks.  Each individual was always tested on the same scanner to mini-mize diff erences in machinery. ❚ Individual results vary from year to year. Th e researchers found that the within-person variation was about 10 times greater than the between-person variation. Th is fi nd-ing suggests that the precision of DXA scan measurements is not that reliable from 1 test to another. The average annual increase in BMD in patients in the alendronate group was 0.0085 g/cm2—which is smaller than the typical year-to-year (within-person) varia-tion of 0.013 g/cm2. It would therefore be difficult to differentiate the medication’s ef-fect from the random variation inherent in DXA scans.❚ Response is favorable after 3 years of treatment. While there is variation in test results from year to year, longer-term fi ndings are more reliable. After 3 years of treatment, 97.5% of patients taking alendro-nate had an increase in hip BMD of at least 0.019 g/cm2, with a strong correlation be-tween hip and spine measurements.  Al-though this represents a relatively small change in Z and T scores, this increase in hip BMD is considered a favorable response that warrants continued treatment. Th ese fi nd-ings are consistent with a previous analy-sis of BMD monitoring in women taking bisphosphonates, in which those who had the largest drop in BMD after the fi rst year of treatment typically had a large gain over the second year.8WHAT’S NEWNow we know early testing is unnecessaryNot many studies are available to provide guidance about the interval between BMD measurements after starting a bisphospho-INSTANT POLL QUESTIONHow long do you typically wait after initiating bisphosphonate therapy before ordering a repeat DXA scan? • 1 year • 2 years• ≥3 years•  It depends on the patient. • Other_____Go to jfponline.comand take our instant poll CONTINUED595_JFP1109   595 10/19/09   11:52:42 AM 1.  Bell KL, Hayen A, Macaskill P, et al. Value of routine monitoring of bone mineral density after starting bisphosphonate treatment: secondary analysis of treatment data. BMJ. 2009;338:b2266.  2.  Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006;17:1726. 3.  MacLean C, Newberry S, et al. Systematic review: compara-tive eff ectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med. 2008;148:197-213.  4.  Agency for Healthcare Research and Quality. United States Pre-ventive Services Task Force. Screening for osteoporosis in post-menopausal women. Available at: http://www.ahrq.gov/clinic/3rduspstf/osteoporosis/osteorr.htm. Accessed October 13, 2009. 5.  Schousboe JT. Cost eff ectiveness of screen-and-treat strategies for low bone mineral density: how do we screen, who do we screen, and who do we treat? Appl Health Econ Health Policy. 2008:6:1-18. 6.  Black DM, Nevitt MC, Cauley J, et al. Design of the fracture inter-vention trial. Osteopor Int. 2003;3(suppl 3):S29-S39. 7.  Cummings S, Black D, Th ompson D, et al. Eff ect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. JAMA. 1998;280:2077-2082. 8.  Cummings S, Palermo B, Browner W, et al. Monitoring osteopo-rosis therapy with bone densitometry: misleading changes and regression to the mean. Fracture Intervention Trial Research Group. JAMA. 2000; 283:1318-1321. 9.  AACE Osteoporosis Task Force, American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract. 2003;9:544-564. 10.  National Osteoporosis Foundation. Clinician’s Guide to Preven-tion and Treatment of Osteoporosis. Washington DC: NOF; 2008. 11.  Management of postmenopausal osteoporosis: position state-ment of the North American Menopause Society. Menopause. 2002;9:84-101. ReferencesThis activity is sponsored by Omnia Education and supported by independent educational grants from Merck & Co., Inc., and QIAGEN Inc.HPV—Past, present,and in practiceThis supplement was submitted by Omnia Education. Selected topics resulted from a process that included a review of needs assessments, quality improvement data, an expert-needs survey, which included medical advisory board input, and peer-reviewed literature.This activity is supported by independent educational grants from Merck & Co., Inc., and QIAGEN Inc.HPV—Past, present, and in practiceNatural history of HPV infections THOMAS C. WRIGHT JR, MD HPV genotyping clinical updateAMERICAN SOCIETY FOR COLPOSCOPY AND CERVICAL PATHOLOGY Integrating HPV vaccination into your practice: Overcoming common barriersBARBARA LEVY, MD, FACOG, FACSOmniatheCMEJ O U R N A LS U P P L E M E N T  T O1.0 FREE CME CREDITwww.jfponline.com Vol 58, No 9  /  September 2009THE OMNIA CME JOURNAL1.0 FREE CME CREDITClick on supplements/newsletters at jfponline.com¢596_JFP1109   596 10/19/09   11:52:47 AM

Bisphosphonate therapy: When not to monitor BMD

Abstract

Similar works

Full text

Available Versions

University of Missouri: MOspace